Sandoz B.V. Page 1/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Bijsluiter 1313-V7

April 2024

Bijsluiter: informatie voor de patiënt

Abatixent 5 mg filmomhulde tabletten

apixaban

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

- 1. What [Nationally Completed Name] is and what it is used for
- 2. What you need to know before you take [Nationally Completed Name]
- 3. How to take [Nationally Completed Name]
- 4. Possible side effects
- 5. How to store [Nationally Completed Name]
- 6. Contents of the pack and other information

1. What [Nationally Completed Name] is and what it is used for

[Nationally Completed Name] contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.

[Nationally Completed Name] is used in adults:

- to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal blood flow to that organ (also known as a systemic embolism). A stroke can be life-threatening and requires immediate medical attention.
- to treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

2. What you need to know before you take [Nationally Completed Name]

Do not take [Nationally Completed Name] if

Sandoz B.V. Page 2/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter

April 2024

1313-V7

• **you are allergic** to apixaban or any of the other ingredients of this medicine (listed in section 6):

- you are **bleeding excessively**;
- you have a **disease in an organ** of the body that increases the risk of serious bleeding (such as **an active or a recent ulcer** of your stomach or bowel, **recent bleeding in your brain**);
- you have a **liver disease** which leads to increased risk of bleeding (hepatic coagulopathy);
- you are **taking medicines to prevent blood clotting** (e.g., warfarin, rivaroxaban, dabigatran or heparin), except when changing anticoagulant treatment, while having a venous or arterial line and you get heparin through this line to keep it open, or if a tube is inserted into your blood vessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:

- an increased risk of bleeding, such as:
 - **bleeding disorders**, including conditions resulting in reduced platelet activity;
 - very high blood pressure, not controlled by medical treatment;
 - you are older than 75 years;
 - you weigh 60 kg or less;
- a severe kidney disease or if you are on dialysis;
- a liver problem or a history of liver problems:

This medicine will be used with caution in patients with signs of altered liver function.

- if you have a **prosthetic heart valve**;
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.

Take special care with [Nationally Completed Name]

• if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.

If you need to have surgery or a procedure which may cause bleeding, your doctor might ask you to temporarily stop taking this medicine for a short while. If you are not sure whether a procedure may cause bleeding ask your doctor.

Children and adolescents

This medicine is not recommended in children and adolescents under 18 years of age.

Other medicines and [Nationally Completed Name]

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Sandoz B.V. Page 3/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter 1313-V7

.1.3 Bijsluiter April 2024

Some medicines may increase the effects of [Nationally Completed Name] and some may decrease its effects. Your doctor will decide, if you should be treated with [Nationally Completed Name] when taking these medicines and how closely you should be monitored.

The following medicines may increase the effects of [Nationally Completed Name] and increase the chance for unwanted bleeding:

- some **medicines for fungal infections** (e.g., ketoconazole, etc.);
- some antiviral medicines for HIV/AIDS (e.g., ritonavir);
- other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.);
- **anti-inflammatory** or **pain medicines** (e.g., acetylsalicylic acid or naproxen). Especially, if you are older than 75 years and are taking acetylsalicylic acid, you may have an increased chance of bleeding;
- medicines for high blood pressure or heart problems (e.g., diltiazem);
- antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin norepinephrine re-uptake inhibitors.

The following medicines may reduce the ability of [Nationally Completed Name] to help prevent blood clots from forming:

- **medicines to prevent epilepsy or seizures** (e.g., phenytoin, etc.);
- St John's Wort (a herbal supplement used for depression);
- medicines to treat tuberculosis or other infections (e.g., rifampicin).

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.

The effects of [Nationally Completed Name] on pregnancy and the unborn child are not known. You should not take this medicine if you are pregnant. **Contact your doctor immediately** if you become pregnant while taking this medicine.

It is not known if [Nationally Completed Name] passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you whether to stop breast-feeding or to stop/not start taking this medicine.

Driving and using machines

[Nationally Completed Name] has not been shown to impair your ability to drive or use machines.

[Nationally Completed Name] contains lactose (a type of sugar) and sodium

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially "sodium-free".

Sandoz B.V. Page 4/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter 1313-V7

April 2024

3. How to take [Nationally Completed Name]

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.

Dose

Swallow the tablet with a drink of water. [Nationally Completed Name] can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take [Nationally Completed Name]. The tablet may be crushed and mixed with water, or 5% glucose in water, or apple juice or apple puree, immediately before you take it.

Instructions for crushing:

- Crush the tablets with a pestle and mortar.
- Transfer all the powder carefully into a suitable container then mix the powder with a little e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above to make a mixture.
- Swallow the mixture.
- Rinse the pestle and mortar you used for crushing the tablet and the container, with a little water or one of the other liquids (e.g., 30 mL), and swallow the rinse.

If necessary, your doctor may also give you the crushed [Nationally Completed Name] tablet mixed in 60 mL of water or 5% glucose in water, through a nasogastric tube.

Take [Nationally Completed Name] as recommended for the following:

To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

The recommended dose is one tablet of [Nationally Completed Name] 5 mg twice a day.

The recommended dose is one tablet of [Nationally Completed Name] **2.5 mg** twice a day if: you have **severely reduced kidney function**;

- two or more of the following apply to you:
 - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater);
 - you are 80 years old or older;
 - your weight is 60 kg or lower.

The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs. The recommended dose is **two tablets** of [Nationally Completed Name] **5 mg** twice a day for the first 7 days, for example, two in the morning and two in the evening.

After 7 days the recommended dose is **one tablet** of [Nationally Completed Name] **5 mg** twice a day, for example, one in the morning and one in the evening.

Sandoz B.V. Page 5/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter 1313-V7

April 2024

For preventing blood clots from re-occurring following completion of 6 months of treatment The recommended dose is one tablet of [Nationally Completed Name] **2.5 mg** twice a day for

example, one in the morning and one in the evening.

Your doctor will decide how long you must continue treatment for.

Your doctor might change your anticoagulant treatment as follows:

Changing from [Nationally Completed Name] to anticoagulant medicines

Stop taking [Nationally Completed Name]. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.

Changing from anticoagulant medicines to [Nationally Completed Name]

Stop taking the anticoagulant medicines. Start treatment with [Nationally Completed Name] at the time you would have had the next dose of anticoagulant medicine, then continue as normal.

Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin) to [Nationally Completed Name]

Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to start taking [Nationally Completed Name].

<u>Changing from [Nationally Completed Name] to anticoagulant treatment containing vitamin K</u> antagonist (e.g., warfarin).

If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take [Nationally Completed Name] for at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking [Nationally Completed Name].

Patients undergoing cardioversion

If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take [Nationally Completed Name] at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.

If you take more [Nationally Completed Name] than you should

Tell your doctor immediately if you have taken more than the prescribed dose of [Nationally Completed Name]. Take the medicine pack with you, even if there are no tablets left.

If you take more [Nationally Completed Name] than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that may reverse antifactor Xa activity may be required.

If you forget to take [Nationally Completed Name]

Take the dose as soon as you remember and:

- take the next dose of [Nationally Completed Name] at the usual time
- then continue as normal.

Sandoz B.V. Page 6/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Bijsluiter 1313-V7

April 2024

If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse

If you stop taking [Nationally Completed Name]

Do not stop taking [Nationally Completed Name] without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common general side effect of this medicine is bleeding which may be potentially life threatening and require immediate medical attention.

The following side effects are known if you take [Nationally Completed Name] to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.

Common side effects (may affect up to 1 in 10 people)

- Bleeding including:
 - in your eyes;
 - in your stomach or bowel;
 - from your rectum;
 - blood in the urine;
 - from your nose;
 - from your gums;
 - bruising and swelling;
- Anaemia which may cause tiredness or paleness;
- Low blood pressure which may make you feel faint or have a quickened heartbeat;
- Nausea (feeling sick);
- Blood tests may show:
 - an increase in gamma-glutamyltransferase (GGT).

Uncommon side effects (may affect up to 1 in 100 people)

- Bleeding:
 - in your brain or in your spinal column;
 - in your mouth or blood in your spit when coughing;
 - into your abdomen, or from the vagina;
 - bright/red blood in the stools;
 - bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site;
 - from a haemorrhoid;
 - tests showing blood in the stools or in the urine;
- Reduced number of platelets in your blood (which can affect clotting);

Sandoz B.V. Page 7/11

Abatixent 5 mg filmomhulde tabletten RVG 125877

1313-V7

1.3.1.3 Bijsluiter April 2024

- Blood tests may show:
 - abnormal liver function;
 - an increase in some liver enzymes;
 - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.
- Skin rash;
- Itching;
- Hair loss;
- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. **Contact your doctor immediately** if you experience any of these symptoms.

Rare side effects (may affect up to 1 in 1,000 people)

- Bleeding:
 - in your lungs or your throat;
 - into the space behind your abdominal cavity;
 - into a muscle.

Very rare side effects (may affect up to 1 in 10,000 people)

• Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (*erythema multiforme*).

Not known (frequency cannot be estimated from the available data)

• Blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising.

The following side effects are known if you take [Nationally Completed Name] to treat or prevent reoccurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.

Common side effects (may affect up to 1 in 10 people)

- Bleeding including:
 - from your nose;
 - from your gums;
 - blood in the urine;
 - bruising and swelling;
 - in your stomach, your bowel, from your rectum;
 - in your mouth;
 - from the vagina;
- Anaemia which may cause tiredness or paleness;
- Reduced number of platelets in your blood (which can affect clotting);
- Nausea (feeling sick);
- Skin rash;
- Blood tests may show:
 - an increase in gamma-glutamyltransferase (GGT) or alanine aminotransferase (ALT).

Uncommon side effects (may affect up to 1 in 100 people)

• Low blood pressure which may make you feel faint or have a quickened heartbeat;

Sandoz B.V. Page 8/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter

April 2024

1313-V7

Bleeding:

- in your eyes;
- in your mouth or blood in your spit when coughing;
- bright/red blood in the stools;
- tests showing blood in the stools or in the urine;
- bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site;
- from a haemorrhoid;
- into a muscle;
- Itching;
- Hair loss;
- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms;
- Blood tests may show:
 - abnormal liver function;
 - an increase in some liver enzymes;
 - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.

Rare side effects (may affect up to 1 in 1,000 people)

- Bleeding:
 - in your brain or in your spinal column;
 - in your lungs.

Not known (frequency cannot be estimated from the available data)

- Bleeding:
 - into your abdomen or the space behind your abdominal cavity.
- Skin rash which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (*erythema multiforme*);
- Blood vessel inflammation (vasculitis) which may result in skin rash or pointed, flat, red, round spots under the skin's surface or bruising.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in <u>Appendix V</u>. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store [Nationally Completed Name]

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of that month.

Sandoz B.V. Page 9/11

Abatixent 5 mg filmomhulde tabletten RVG 125877 1.3.1.3 Biisluiter 1313-V7

April 2024

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [Nationally Completed Name] contains

- The active substance is apixaban. Each tablet contains 5 mg of apixaban.
- The other ingredients are:
 - Tablet core: lactose monohydrate, cellulose, microcrystalline, croscarmellose sodium, sodium laurylsulfate, magnesium stearate
 - Film coat: hypromellose, hydroxypropylcellulose, macrogol 6000, titanium dioxide (E171), iron oxide, red (E172), iron oxide, yellow (E172)

See section 2 "[Nationally Completed Name] contains lactose (a type of sugar) and sodium".

What [Nationally Completed Name] looks like and contents of the pack

[Nationally Completed Name] 5 mg film-coated tablets (tablets) are pink, oval, biconvex, film-coated tablets, debossed with "AX" on one side and "5" on the other side, with a width of 5.0 - 5.7 mm and length of 9.6 - 10.3 mm.

The product is available in

NL/H/5035

Alu-PVC/PVdC blisters of 10, 12, 14, 20, 28, 30, 56, 60, 100, 168, 180 and 200 film-coated tablets (tablets).

Alu-PVC/PVdC perforated unit dose blisters of 20 x 1, 30 x 1, 60 x 1, 100 x 1, 168 x 1 and 180 x 1 film-coated tablets (tablets).

NL/5036/5037/5038

Alu-PVC/PVdC blisters of 10, 12, 14, 20, 28, 30, 56, 60, 100, 168, 180 and 200 film-coated tablets (tablets).

Alu-PVC/PVdC perforated unit dose blisters of 20x1, 60x1 100x1 and 168x1 film-coated tablets (tablets).

NL/H/5035/5037/5038

HDPE/PP bottles of 200 film-coated tablets

Not all pack sizes may be marketed.

Patient Alert Card: handling information

Sandoz B.V. Page 10/11

Abatixent 5 mg filmomhulde tabletten RVG 125877

1313-V7

1.3.1.3 Bijsluiter April 2024

Inside the [Nationally Completed Name] pack together with the package leaflet you will find a Patient Alert Card or your health care provider might give you a similar card.

This Patient Alert Card includes information that will be helpful to you and alert other doctors that you are taking [Nationally Completed Name]. You should keep this card with you at all times.

- 1. Take the card
- 2. Complete the following sections or ask your doctor to do it:
 - Name:
 - Birth Date:
 - Indication:
 - Dose:mg twice daily
 - Doctor's Name:
 - Doctor's telephone:
- 3. Fold the card and keep it with you at all times

Houder van de vergunning voor het in de handel brengen en fabrikant Vergunninghouder

Sandoz B.V. Hospitaaldreef 29 1315 RC Almere Nederland

Fabrikant

Lek Pharmaceuticals, d.d. Verovškova ulica 57 1526 Ljubljana Slovenië

Lek SA Ul. Podlipie 16 c 95 010 Strykow Polen

In het register ingeschreven onder

RVG 125877

Dit medicijn is geregistreerd in lidstaten van de Europese Economische Ruimte en in het Verenigd Koninkrijk (Noord-Ierland) onder de volgende namen:

Nederland Abatixent 5 mg filmomhulde tabletten

Oostenrijk Abatixent 5 mg – Filmtabletten

Bulgarije АБАТИКСЕНТ 5 mg филмирани таблетки

Abatixent 5 mg film-coated tablets

Estland Abatixent

Litouwen Abatixent 5 mg plèvele dengtos tabletės Kroatië Abatixent 5 mg filmom obložene tablete

Sandoz B.V. Page 11/11

1313-V7

Abatixent 5 mg filmomhulde tabletten

RVG 125877

1.3.1.3 Bijsluiter April 2024

Polen Abatixent

Roemenië Abatixent 5 mg comprimate filmate Abatixent 5 mg filmsko obložene tablete Slovenië

Deze bijsluiter is voor het laatst goedgekeurd in februari 2024